Transpire Bio Inc. Strengthens Leadership For Commercial Growth With The Appointment Of R. LaDuane Clifton As Chief Financial Officer

Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company developing inhaled treatments for both pulmonary and systemic diseases, has announced the appointment of R. LaDuane Clifton as its new Chief Financial Officer.

Dr. Xian-Ming Zeng, Chief Executive Officer of Transpire Bio, explained that the company is preparing for its transition from a clinical-stage organization to a commercial-stage biopharmaceutical company. As part of this shift, the leadership team is being strengthened to support the upcoming phase of growth and operational expansion. He said Mr. Clifton’s appointment reflects this strategy and highlighted his extensive background in public company finance, global financial operations, and organizational leadership.

Beyond his experience in public company financial management, Mr. Clifton brings a broad understanding of the biopharmaceutical industry. His background includes work across drug development and commercialization, manufacturing, managed care contracting, compliance, investor relations, and business development. This combination of strategic and operational experience positions him to play a key role in Transpire Bio’s continued advancement.

In his statement, Mr. Clifton expressed his enthusiasm for joining Transpire Bio and supporting the company’s priorities as it scales. He noted that he is excited to work with the leadership team during a period of significant growth and development.

Before joining Transpire Bio, Mr. Clifton served as Chief Financial Officer and Treasurer of Zevra Therapeutics Inc., a commercial-stage company focused on therapeutics for rare diseases. His career also includes senior finance roles such as Chief Financial Officer, Secretary, and Treasurer at The LGL Group Inc., and Chief Financial Officer of a21 Inc.. Earlier in his career, he worked as an auditor at KPMG LLP and held finance and healthcare contracting positions at Aetna Inc.. 

With this appointment, Transpire Bio continues building the leadership infrastructure needed to support its long-term strategy of bringing inhaled therapies to patients with serious pulmonary and systemic conditions.